TWI627954B - 急性骨髓性白血病(aml)之新穎組合治療 - Google Patents

急性骨髓性白血病(aml)之新穎組合治療 Download PDF

Info

Publication number
TWI627954B
TWI627954B TW103142020A TW103142020A TWI627954B TW I627954 B TWI627954 B TW I627954B TW 103142020 A TW103142020 A TW 103142020A TW 103142020 A TW103142020 A TW 103142020A TW I627954 B TWI627954 B TW I627954B
Authority
TW
Taiwan
Prior art keywords
compound
day
formula
mdm2
administered
Prior art date
Application number
TW103142020A
Other languages
English (en)
Chinese (zh)
Other versions
TW201526890A (zh
Inventor
布萊恩 席金斯
Brian Higgins
關 尼可斯
Gwen NICHOLS
凱薩琳E 派克曼
Kathryn E. Packman
Original Assignee
赫孚孟拉羅股份公司
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52014047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI627954(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 赫孚孟拉羅股份公司, F. Hoffmann-La Roche Ag filed Critical 赫孚孟拉羅股份公司
Publication of TW201526890A publication Critical patent/TW201526890A/zh
Application granted granted Critical
Publication of TWI627954B publication Critical patent/TWI627954B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/77Polymers containing oxygen of oxiranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
TW103142020A 2013-12-05 2014-12-03 急性骨髓性白血病(aml)之新穎組合治療 TWI627954B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912152P 2013-12-05 2013-12-05
US61/912,152 2013-12-05

Publications (2)

Publication Number Publication Date
TW201526890A TW201526890A (zh) 2015-07-16
TWI627954B true TWI627954B (zh) 2018-07-01

Family

ID=52014047

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107105068A TWI678204B (zh) 2013-12-05 2014-12-03 急性骨髓性白血病(aml)之新穎組合治療
TW103142020A TWI627954B (zh) 2013-12-05 2014-12-03 急性骨髓性白血病(aml)之新穎組合治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW107105068A TWI678204B (zh) 2013-12-05 2014-12-03 急性骨髓性白血病(aml)之新穎組合治療

Country Status (31)

Country Link
US (5) US20160303158A1 (es)
EP (1) EP3077004B1 (es)
JP (3) JP6297695B2 (es)
KR (1) KR101862955B1 (es)
CN (1) CN105792847B (es)
AR (1) AR098576A1 (es)
AU (1) AU2014359422B2 (es)
BR (1) BR112016009669B1 (es)
CA (1) CA2926307C (es)
CL (1) CL2016001345A1 (es)
CR (1) CR20160173A (es)
DK (1) DK3077004T3 (es)
EA (1) EA201690785A1 (es)
ES (1) ES2785203T3 (es)
HK (1) HK1222808A1 (es)
HR (1) HRP20200566T1 (es)
HU (1) HUE049434T2 (es)
IL (1) IL244888B (es)
LT (1) LT3077004T (es)
MA (1) MA39040A1 (es)
MX (1) MX370618B (es)
PE (1) PE20160591A1 (es)
PH (1) PH12016500933A1 (es)
PL (1) PL3077004T3 (es)
PT (1) PT3077004T (es)
RS (1) RS60142B1 (es)
SG (1) SG11201604504VA (es)
SI (1) SI3077004T1 (es)
TW (2) TWI678204B (es)
WO (1) WO2015082384A1 (es)
ZA (1) ZA201602829B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス,インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
PE20160591A1 (es) * 2013-12-05 2016-06-11 Hoffmann La Roche Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma)
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CA2961029A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
CN107614003A (zh) 2015-03-20 2018-01-19 艾瑞朗医疗公司 拟肽大环化合物及其用途
CN108348571B (zh) * 2015-09-03 2022-03-22 艾瑞朗医疗公司 拟肽大环化合物及其用途
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
EP3463358A4 (en) * 2016-06-06 2020-07-22 Celgene Corporation TREATMENT OF HEMATOLOGICAL MALIGNANT TUMOR WITH 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2- DIFLUOROACETAMIDE
JP6848047B2 (ja) * 2016-08-08 2021-03-24 フェイ シアオ, スピロインドロンポリエチレングリコールカーボネート系化合物及びその組成物、調製方法及びその使用
MX2019005623A (es) 2016-11-15 2019-08-14 Novartis Ag Dosis y regimen para inhibidores de la interaccion hdm2-p53.
JP6617208B2 (ja) * 2017-03-31 2019-12-11 ノバルティス アーゲー 血液腫瘍におけるhdm2−p53相互作用阻害剤の用量およびレジメン
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP7126556B2 (ja) 2018-09-28 2022-08-26 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
AU2020323033A1 (en) * 2019-07-26 2021-04-22 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease
WO2022241036A1 (en) * 2021-05-13 2022-11-17 Nkarta, Inc. Dosing regimens for cancer immunotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101773408A (zh) * 2010-01-15 2010-07-14 平荧 多功能排针结合电凝固技术提升下垂皮肤的装置及方法
TW201341357A (zh) * 2012-03-15 2013-10-16 Hoffmann La Roche 經取代吡咯啶-2-羧醯胺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003241326B2 (en) * 2002-05-02 2008-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
DE102005012681A1 (de) * 2005-03-18 2006-09-21 Weber, Lutz, Dr. Neue 1,5-Dihydro-pyrrol-2-one
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CA2800519A1 (en) * 2010-04-09 2011-10-13 The Regents Of The University Of Michigan Biomarkers for mdm2 inhibitors for use in treating disease
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
PE20160591A1 (es) * 2013-12-05 2016-06-11 Hoffmann La Roche Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma)
US9657351B2 (en) * 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101773408A (zh) * 2010-01-15 2010-07-14 平荧 多功能排针结合电凝固技术提升下垂皮肤的装置及方法
TW201341357A (zh) * 2012-03-15 2013-10-16 Hoffmann La Roche 經取代吡咯啶-2-羧醯胺

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"A Study of as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia", 網址:https://clinicaltrials.gov/ct2/show/, 網頁日期:2013年1月18日. Kojima K et al,"MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy", Blood, 2005 Nov 1; 106(9): 3150–3159. *
"A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia", 網址:https://clinicaltrials.gov/ct2/show/NCT01773408, 網頁日期:2013年1月18日.
Kojima K et al,"MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy", Blood, 2005 Nov 1; 106(9): 3150–3159.

Also Published As

Publication number Publication date
HK1222808A1 (zh) 2017-07-14
MX2016007170A (es) 2016-09-08
PT3077004T (pt) 2020-04-16
EP3077004B1 (en) 2020-02-19
JP2018111700A (ja) 2018-07-19
AR098576A1 (es) 2016-06-01
PL3077004T3 (pl) 2020-08-10
IL244888A0 (en) 2016-05-31
BR112016009669B1 (pt) 2023-01-24
CL2016001345A1 (es) 2017-04-07
US20220031726A1 (en) 2022-02-03
MX370618B (es) 2019-12-17
CR20160173A (es) 2016-06-08
JP2016539160A (ja) 2016-12-15
CA2926307A1 (en) 2015-06-11
JP6918724B2 (ja) 2021-08-11
JP6297695B2 (ja) 2018-03-20
KR20160070190A (ko) 2016-06-17
TW201526890A (zh) 2015-07-16
US20200253999A1 (en) 2020-08-13
AU2014359422B2 (en) 2020-03-05
PE20160591A1 (es) 2016-06-11
SI3077004T1 (sl) 2020-07-31
PH12016500933A1 (en) 2016-06-27
DK3077004T3 (da) 2020-04-27
RS60142B1 (sr) 2020-05-29
US20160303158A1 (en) 2016-10-20
EP3077004A1 (en) 2016-10-12
EA201690785A1 (ru) 2016-10-31
AU2014359422A1 (en) 2016-04-28
US9956243B2 (en) 2018-05-01
SG11201604504VA (en) 2016-07-28
BR112016009669A8 (pt) 2020-04-07
ES2785203T3 (es) 2020-10-06
CN105792847A (zh) 2016-07-20
CA2926307C (en) 2021-11-16
KR101862955B1 (ko) 2018-05-31
JP2021091690A (ja) 2021-06-17
MA39040A1 (fr) 2018-01-31
CN105792847B (zh) 2019-11-08
IL244888B (en) 2020-11-30
US20230381215A1 (en) 2023-11-30
TW201840310A (zh) 2018-11-16
WO2015082384A1 (en) 2015-06-11
HRP20200566T1 (hr) 2020-06-26
HUE049434T2 (hu) 2020-09-28
ZA201602829B (en) 2017-04-26
US20150157603A1 (en) 2015-06-11
TWI678204B (zh) 2019-12-01
LT3077004T (lt) 2020-05-11

Similar Documents

Publication Publication Date Title
TWI627954B (zh) 急性骨髓性白血病(aml)之新穎組合治療
RU2717331C2 (ru) Применение антагонистов рецептора ep4 для лечения nash-ассоциированного рака печени
US20190262267A1 (en) Pharmaceutical solution having a toxicity-reducing effect for antitumor drugs, and pharmaceutical composition comprising same
KR101628448B1 (ko) 암 치료에 사용하기 위한 베무라페닙 및 인터페론을 포함하는 병용 요법
US20210040224A1 (en) Cd47 blockade therapy with cd38 antibody
US20190241660A1 (en) Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer
US20200230247A1 (en) Combination therapies comprising targeted therapeutics
US10357478B2 (en) Polyamide compound and pharmaceutical composition for treating mitochondrial genetic diseases
US20190365680A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
US20220287993A1 (en) Pharmaceutical composition comprising hdac inhibitor and anti-pd1 antibody or anti pd-l1 antibody
US20210186978A1 (en) Combination therapy
Chatterji et al. Microtubules as Anti-Cancer Drug Targets
WO2009104150A1 (en) Combination comprising bosentan for treating ovarian cancer